Skip to main content

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $11.64: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.41; Below-average business quality.

Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, operating four segments (Connected Technology Solutions, Essential Dental Solutions, Orthodontic/Implant Solutions, Wellspect Healthcare) in ~140 countries. Revenue is... Read more

$11.64+9.0% A.UpsideScore 4.9/10#20 of 25 Medical Instruments & Supplies
Stop $10.92Target $12.69(analyst − 10%)A.R:R 1.1:1
Analyst target$14.10+21.1%15 analysts
$12.69our TP
$11.64price
$14.10mean
$10
$18

Sell if holding. Engine safety override at $11.64: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.41; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.

Passes 4/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Customer: limited number of distributors
Quality below floor (3.6 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)7.4
Mkt Cap$2.3B
EV/EBITDA7.4
Profit Mgn-16.3%
ROE-36.4%
Rev Growth6.2%
Beta1.00
Dividend5.04%
Rating analysts21

Quality Signals

Piotroski F8/9

Options Flow

P/C2.41bearish
IV81%elevated
Max Pain$3-78.5% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHCustomerlimited number of distributors
    10-K Item 1A: 'We generate a substantial portion of our revenue through a limited number of distributors who we also rely on to provide important service and support to end-users'

Material Events(8-K, last 90d)

  • 2026-02-24Item 5.02LOW
    Board increased from 11 to 13 directors; James D. Forbes and Brian P. McKeon appointed effective Feb 27, 2026. Forbes to Compensation Committee, McKeon to Audit/Finance and Science/Technology Committees.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.4
Obv
1.0
Ma Position
1.0
Macd
3.1
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA, MA slope -4.3%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.6
Growth Rank
2.3
Value Rank
9.6

Unprofitable operations — net margin -16.3%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Operating Margin
0.7
Roa
1.8
Fcf Quality
4.1
Moat
5.0
Current Ratio
5.5
Gross Margin
6.0
Piotroski F
8.9
FCF-positive but moderate margins (FCF margin 3%, FCF yield 4.6%)No competitive moatStrong Piotroski F-Score: 8/9
GatesMomentum 2.0<4.5A.R:R 1.1 < 1.5@spotDeath cross (50MA < 200MA)EARNINGS PROXIMITY 5d<=7dInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
49 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $11.26Resistance $13.01

Price Targets

$11
$13
A.Upside+9.0%
A.R:R1.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.6 < 4.0)
! Momentum score 2.0/10 — below 4.5 minimum
! Reward/Risk 1.1:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is XRAY stock a buy right now?

Sell if holding. Engine safety override at $11.64: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.41; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $10.92. Score 4.9/10, moderate confidence.

What is the XRAY stock price target?

Take-profit target: $12.69 (+9.0% upside). Prior stop was $10.92. Stop-loss: $10.92.

What are the risks of investing in XRAY?

Concentration risk — Customer: limited number of distributors; Quality below floor (3.6 < 4.0).

Is XRAY overvalued or undervalued?

DENTSPLY SIRONA Inc. trades at a P/E of N/A (forward 7.4). TrendMatrix value score: 8.2/10. Verdict: Sell.

What do analysts say about XRAY?

21 analysts cover XRAY with a consensus score of 3.5/5. Average price target: $14.

What does DENTSPLY SIRONA Inc. do?Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, operating...

Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, operating four segments (Connected Technology Solutions, Essential Dental Solutions, Orthodontic/Implant Solutions, Wellspect Healthcare) in ~140 countries. Revenue is generated primarily through a limited number of distributors to dental practitioners globally.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · ATRC (AtriCure, Inc.) · NVST (Envista Holdings Corporation)